Alpha Tau Completes Enrollment in Pivotal U.S. Skin Cancer Study, Nearing FDA Approval Path

summarizeSummary

Alpha Tau Medical announced the completion of patient enrollment in its ReSTART pivotal trial for recurrent cutaneous squamous cell carcinoma, marking a critical step towards potential FDA pre-market approval for its Alpha DaRT therapy.

check_boxKey Events · Product Development and Regulatory · DRTS

• Pivotal U.S. Study Enrollment Completed

  Alpha Tau Medical has completed patient enrollment (88 patients) in its ReSTART pivotal trial, evaluating Alpha DaRT for recurrent cutaneous squamous cell carcinoma (cSCC). This is the first U.S. pivotal study for the company to complete enrollment.

• Advances Towards FDA Approval

  This milestone is a critical step towards potential FDA pre-market approval (PMA) for Alpha DaRT in cSCC, an indication for which the therapy has Breakthrough Device Designation. The company initiated the modular PMA application in January 2026.

• Addresses Unmet Medical Need

  The ReSTART trial targets recurrent cSCC, the second most common form of skin cancer, where there is a significant unmet need for patients who have exhausted surgical and conventional treatment options.

auto_awesomeAnalysis · DRTS · Industrial Applications And Services

This announcement signifies a major de-risking event for Alpha Tau Medical, as completing enrollment in a pivotal U.S. study is a crucial prerequisite for FDA pre-market approval (PMA). The Alpha DaRT therapy has already received Breakthrough Device Designation for this indication, and the company has initiated the modular PMA application process. This milestone brings Alpha Tau significantly closer to potential commercialization of its Alpha DaRT technology for recurrent cutaneous squamous cell carcinoma, addressing a significant unmet medical need. Investors should monitor the progress of the PMA submission and subsequent data readouts.